US 7,557,139 B2
Triptolide analogs for the treatment of autoimmune and inflammatory disorders
Hariharan Venkatesan, San Diego, Calif. (US); James P. Snyder, Atlanta, Ga. (US); Dennis C. Liotta, Atlanta, Ga. (US); and Susheng Wang, Clarkston, Ga. (US)
Assigned to Emory University, Atlanta, Ga. (US)
Filed on Aug. 17, 2004, as Appl. No. 10/919,824.
Prior Publication US 2006/0040907 A1, Feb. 23, 2006
Int. Cl. A01N 43/20 (2006.01); A01N 45/00 (2006.01)
U.S. Cl. 514—475  [549/336] 28 Claims
 
1. A method for the treatment of an autoimmune or inflammatory disease in a host comprising administering to the host an effective amount of a compound of the formula (II), (IV) or (III):

OG Complex Work Unit Drawing
or its pharmaceutically acceptable salt or prodrug thereof, wherein:
(a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
(b) A, B, D and E are O; and
R1, R2, R3, R4, R5 and R6 are independently hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl,
optionally in a pharmaceutically acceptable carrier.